CA3046638A1 - Formulations pour administration efficace de cannabinoides - Google Patents

Formulations pour administration efficace de cannabinoides Download PDF

Info

Publication number
CA3046638A1
CA3046638A1 CA3046638A CA3046638A CA3046638A1 CA 3046638 A1 CA3046638 A1 CA 3046638A1 CA 3046638 A CA3046638 A CA 3046638A CA 3046638 A CA3046638 A CA 3046638A CA 3046638 A1 CA3046638 A1 CA 3046638A1
Authority
CA
Canada
Prior art keywords
oil
lozenge
cannabinoids
thc
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3046638A
Other languages
English (en)
Inventor
Benjamin F. Ross
Jerry B. Gin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bennes Inc
Original Assignee
Bennes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bennes Inc filed Critical Bennes Inc
Publication of CA3046638A1 publication Critical patent/CA3046638A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

L'invention concerne des pastilles comprenant de la cellulose d'éthyle et des cannabinoïdes pour une administration rapide et efficace de cannabinoïdes médicaux. La pastille est appropriée pour l'administration du(des) cannabinoïde(s) à travers la muqueuse buccale dans la circulation sanguine. Des modes de réalisation de la pastille sont décrits qui comprennent des additifs qui atténuent d'autres problèmes liés à l'administration de cannabinoïdes. Les additifs décrits comprennent de la gomme xanthane pour atténuer le syndrome de la bouche sèche, des huiles essentielles pour des activités aromatisantes et antibactériennes, du zinc pour l'amélioration de l'haleine, des exhausteurs de perméation et des bicarbonates de métaux alcalins pour réduire l'acidité dans la bouche. L'invention concerne également des méthodes de fabrication des pastilles et leur utilisation dans le traitement d'états pathologiques.
CA3046638A 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoides Abandoned CA3046638A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420981P 2016-11-11 2016-11-11
US62/420,981 2016-11-11
PCT/US2017/061202 WO2018089863A1 (fr) 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoïdes

Publications (1)

Publication Number Publication Date
CA3046638A1 true CA3046638A1 (fr) 2018-05-17

Family

ID=62110287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3046638A Abandoned CA3046638A1 (fr) 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoides

Country Status (3)

Country Link
EP (1) EP3538078A4 (fr)
CA (1) CA3046638A1 (fr)
WO (1) WO2018089863A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820530A4 (fr) * 2018-07-10 2022-03-30 Cardinal Advisory Limited Formulation de composés cannabinoïdes

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3681525A4 (fr) * 2017-09-15 2020-09-02 Zelda Therapeutics Operations Pty Ltd Composition et méthode de traitement de l'autisme
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
EP3745884A1 (fr) 2018-01-31 2020-12-09 Canopy Holdings, Llc Poudre de chanvre
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
CN108703963B (zh) * 2018-07-02 2023-04-14 宁夏医科大学 茴香脑在制备治疗神经病理性疼痛药物中的用途
SG11202101235QA (en) * 2018-08-07 2021-03-30 Ilylt Llc Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
CN109758450B (zh) * 2019-03-06 2021-01-29 天津医科大学 一种抗肿瘤新化合物、及其制备方法和用途
US20200323935A1 (en) * 2019-04-10 2020-10-15 G.I. Pharmaceuticals, Inc. dba E2BIO CONSULTANTS, INC. Novel method for the treatment of dyspepsia, food and medicine intolerances, irritable bowel syndrome and other functional gastrointestinal conditions
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3040532C (fr) * 2019-04-17 2021-12-21 Medcan Pharma A/S Pastille pour administration amelioree de cannabinoides
CA3040547C (fr) * 2019-04-17 2021-12-07 Medcan Pharma A/S Formulation de pastille de cannabinoide
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US20210251950A1 (en) * 2019-07-08 2021-08-19 Aaron Miles System and Method for Incorporating CBD/THC Cannabinoid Nanoparticle Carrier Compositions into Particulate Foods and Food Additives
AU2020331290A1 (en) * 2019-08-09 2022-03-03 Healthaide Inc. CBD formulations and uses thereof
WO2021195540A1 (fr) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Composition à base de cannabinoïdes pour l'atténuation d'effets viraux
EP4304558A1 (fr) * 2021-03-09 2024-01-17 Nutrition & Biosciences USA 1, LLC Composition d'oléogel comprenant une éthylcellulose et un ingrédient actif huileux
WO2023114529A2 (fr) * 2021-12-17 2023-06-22 Bennes, Inc. Formulations pharmacoactives pour administration de composés psychédéliques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539069A4 (fr) * 2002-05-31 2007-11-14 Univ Mississippi Administration par voie transmuqueuse de cannabinoides
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
JP5704925B2 (ja) * 2008-02-08 2015-04-22 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−カンナビノイドコンジュゲート
US9186386B2 (en) * 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
AU2015279612A1 (en) * 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820530A4 (fr) * 2018-07-10 2022-03-30 Cardinal Advisory Limited Formulation de composés cannabinoïdes

Also Published As

Publication number Publication date
EP3538078A1 (fr) 2019-09-18
EP3538078A4 (fr) 2020-07-08
WO2018089863A1 (fr) 2018-05-17

Similar Documents

Publication Publication Date Title
CA3046638A1 (fr) Formulations pour administration efficace de cannabinoides
US11844763B2 (en) Pharmaceutical composition and method of manufacturing
US11938160B2 (en) Pharmaceutical composition and method of manufacturing
US9433601B2 (en) Chewing gum compositions comprising cannabinoids
US20160058866A1 (en) Alternative solutions for the administration of cannabis derived botanical products
CA2454644A1 (fr) Formulations de cannabinoides liquides administrees par les muqueuses
US11730715B2 (en) Consumable compositions and methods of producing the same
CN102742714A (zh) 一种祛烟瘾清心醒脑的口香糖
CA2893277C (fr) Composition comprenant du raphanus, du theobroma et de la passiflora pour le traitement de l'abus d'opioides et d'alcool
US20220062360A1 (en) Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US9597278B2 (en) Compositions and methods for alleviating hyposalivation and for providing oral comfort
WO2021188612A1 (fr) Compositions médicamenteuses à base de cannabinoïdes, procédés de fabrication et méthodes de traitement
US20230023342A1 (en) Chewing gum containing synergistic medicinal compounds
US20240123010A1 (en) Pharmaceutical composition and method of manufacturing
US20220257689A1 (en) Chewing gum compositions for the treatment of menstrual pain
TWI222882B (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230512